EP3346912A4 - Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale - Google Patents

Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale Download PDF

Info

Publication number
EP3346912A4
EP3346912A4 EP16845218.3A EP16845218A EP3346912A4 EP 3346912 A4 EP3346912 A4 EP 3346912A4 EP 16845218 A EP16845218 A EP 16845218A EP 3346912 A4 EP3346912 A4 EP 3346912A4
Authority
EP
European Patent Office
Prior art keywords
cerebro
microbiome
therapeutics
conditions associated
derived diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16845218.3A
Other languages
German (de)
English (en)
Other versions
EP3346912A1 (fr
Inventor
Zachary APTE
Jessica RICHMAN
Daniel Almonacid
Siavosh Rezvan BEHBAHANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psomagen Inc
Original Assignee
uBiome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by uBiome Inc filed Critical uBiome Inc
Publication of EP3346912A1 publication Critical patent/EP3346912A1/fr
Publication of EP3346912A4 publication Critical patent/EP3346912A4/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Wood Science & Technology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Disabilities (AREA)
  • Social Psychology (AREA)
EP16845218.3A 2015-09-09 2016-09-09 Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale Pending EP3346912A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562215939P 2015-09-09 2015-09-09
US201562216028P 2015-09-09 2015-09-09
US201562216042P 2015-09-09 2015-09-09
US201562216035P 2015-09-09 2015-09-09
US201562216016P 2015-09-09 2015-09-09
PCT/US2016/051155 WO2017044885A1 (fr) 2015-09-09 2016-09-09 Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale

Publications (2)

Publication Number Publication Date
EP3346912A1 EP3346912A1 (fr) 2018-07-18
EP3346912A4 true EP3346912A4 (fr) 2019-08-21

Family

ID=58240338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845218.3A Pending EP3346912A4 (fr) 2015-09-09 2016-09-09 Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale

Country Status (5)

Country Link
EP (1) EP3346912A4 (fr)
CN (1) CN108348167B (fr)
AU (1) AU2016321333A1 (fr)
CA (1) CA3006044A1 (fr)
WO (1) WO2017044885A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015335907A1 (en) 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
WO2018094376A1 (fr) * 2016-11-21 2018-05-24 uBiome, Inc. Procédé et système pour caractériser une affection liée à une céphalée
WO2018223146A1 (fr) * 2017-06-02 2018-12-06 uBiome, Inc. Procédé et système destinés à la caractérisation de troubles liés au sommeil apparentés à un microorganisme
US11154240B2 (en) 2019-04-02 2021-10-26 Kpn Innovations Llc Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance
US11289206B2 (en) 2020-06-02 2022-03-29 Kpn Innovations, Llc. Artificial intelligence methods and systems for constitutional analysis using objective functions
US11211158B1 (en) 2020-08-31 2021-12-28 Kpn Innovations, Llc. System and method for representing an arranged list of provider aliment possibilities
CN113096818B (zh) * 2021-04-21 2023-05-30 西安电子科技大学 基于ode和grud的急性病症发生几率的评估方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176774A1 (fr) * 2012-05-25 2013-11-28 Arizona Board Of Regents Marqueurs de microbiome et thérapies pour troubles du spectre autistique
US20140301995A1 (en) * 2011-10-12 2014-10-09 Gut Guide Oy Raising and Diagnosing of Serotonin Level
WO2014179965A1 (fr) * 2013-05-09 2014-11-13 The Procter & Gamble Company Procédé et système d'identification d'un marqueur biologique
US20150211078A1 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (fr) * 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
US20160232280A1 (en) * 2014-10-21 2016-08-11 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228721A1 (en) * 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
US8889361B2 (en) * 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
GB2497007B (en) * 2008-11-07 2013-08-07 Sequenta Inc Methods of monitoring disease conditions by analysis of the full repertoire of the V-D junction or D-J junction sequences of an individual
US20120149584A1 (en) * 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
AU2011258875B2 (en) * 2010-05-25 2016-05-05 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
CN103517991A (zh) * 2010-10-27 2014-01-15 昆特拜克股份公司 通过包括嵌入物分子的探针捕获目标dna和rna
US9689044B2 (en) * 2011-01-26 2017-06-27 The Brigham And Women's Hospital, Inc. Assays and methods to sequence microbes directly from immune complexes
AU2012225310B2 (en) * 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
BR112014023005A2 (pt) * 2012-03-17 2017-07-18 Univ California diagnóstico rápido e tratamentos personalizados para acne
CN107435070A (zh) * 2012-04-12 2017-12-05 维里纳塔健康公司 拷贝数变异的检测和分类
JP6445426B2 (ja) * 2012-05-10 2018-12-26 ザ ジェネラル ホスピタル コーポレイション ヌクレオチド配列を決定する方法
DK3401400T3 (da) * 2012-05-25 2019-06-03 Univ California Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN104540962B (zh) * 2012-08-01 2017-09-19 深圳华大基因研究院 糖尿病生物标志物及其应用
RU2664479C2 (ru) * 2013-02-04 2018-08-17 Серес Терапеутикс, Инк. Композиции и способы
US10253377B2 (en) * 2013-04-05 2019-04-09 Wayne State University Systems and methods to assess microbiomes and treatments thereof
WO2015074054A1 (fr) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Amélioration de la santé microbienne dans l'intestin de mammifères
CN104195145B (zh) * 2014-07-15 2017-01-18 浙江大学 肝硬化的生物标志物及其应用
US10265009B2 (en) * 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140301995A1 (en) * 2011-10-12 2014-10-09 Gut Guide Oy Raising and Diagnosing of Serotonin Level
WO2013176774A1 (fr) * 2012-05-25 2013-11-28 Arizona Board Of Regents Marqueurs de microbiome et thérapies pour troubles du spectre autistique
WO2014179965A1 (fr) * 2013-05-09 2014-11-13 The Procter & Gamble Company Procédé et système d'identification d'un marqueur biologique
US20150211078A1 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (fr) * 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
US20160232280A1 (en) * 2014-10-21 2016-08-11 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017044885A1 *

Also Published As

Publication number Publication date
AU2016321333A1 (en) 2018-04-26
WO2017044885A1 (fr) 2017-03-16
EP3346912A1 (fr) 2018-07-18
CN108348167B (zh) 2022-06-03
CN108348167A (zh) 2018-07-31
CA3006044A1 (fr) 2017-03-16

Similar Documents

Publication Publication Date Title
EP3347495A4 (fr) Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé gastro-intestinale
EP3209803A4 (fr) Procédé et système de diagnostic et de thérapie fondés sur le microbiome
EP3347496A4 (fr) Méthode et système de diagnostics dérivés du microbiome et traitements thérapeutiques pour la santé bucco-dentaire
EP3317428A4 (fr) Procédé et système destinés à un essai diagnostique
EP3333660A4 (fr) Système de diagnostic de prédicteur d'anomalies et procédé de diagnostic de prédicteur d'anomalies
EP3346912A4 (fr) Procédé et système pour des diagnostics dérivés du microbiome et agents thérapeutiques pour des affections associées à la santé cérébro-carniofaciale
EP3283086A4 (fr) Procédé et système de diagnostic et de traitement dérivés du microbiome pour des pathologies associées aux caractéristiques fonctionnelles du microbiome
EP3090416A4 (fr) Procede et systeme de surveillance
EP3347367A4 (fr) Procédé et système de diagnostic et de thérapie dérivés du microbiome pour la vaginose bactérienne
EP3328273A4 (fr) Procédé et système permettant de surveiller et d'améliorer l'attention
EP3333661A4 (fr) Système de diagnostic de prédicteur d'anomalie et procédé de diagnostic de prédicteur d'anomalie
EP3346910A4 (fr) Procédé et système pour diagnostics dérivés du microbiome et agents thérapeutiques contre l'eczéma
EP3299918A4 (fr) Système de diagnostic d'anomalies et procédé de diagnostic d'anomalies
EP3283648A4 (fr) Méthode et système de diagnostic dérivé du microbiome et de traitement de problèmes thérapeutiques destinés à des problèmes de santé neurologiques
EP3229093A4 (fr) Procédé de diagnostic d'anomalie et système de diagnostic d'anomalie
EP3273648A4 (fr) Système et procédé
EP3283085A4 (fr) Procédé et système pour diagnostics et thérapies dérivés du microbiome pour affections associées à des éléments taxonomiques du microbiome
EP3346911A4 (fr) Procédé et système pour diagnostics dérivés du microbiome et agents thérapeutiques pour une maladie infectieuse ou d'autres états de santé associés à l'utilisation d'antibiotiques
EP3105965A4 (fr) Système et procédé de ré-hébergement de connexion
EP3283084A4 (fr) Procédé et système de caractérisation, de diagnostics et de traitements dérivés du microbiome pour des dermatoses
EP3283650A4 (fr) Procédé et système pour la caractérisation, le diagnostic et le traitement dérivés du microbiome d'affections associées à des caractéristiques fonctionnelles
EP3111700A4 (fr) Système et procédé de transfert spécifique à un ue
EP3283649A4 (fr) Procédé et système pour la caractérisation, le diagnostic et le traitement dérivés du microbiome de pathologies cardiovasculaires
EP3120162A4 (fr) Système et procédé pour effectuer un diagnostic de transformateur
EP3335380A4 (fr) Procédé et système de diagnostic de transaction

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180406

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G16B 20/00 20190101ALI20190410BHEP

Ipc: G16B 40/20 20190101ALI20190410BHEP

Ipc: C12Q 1/68 20180101ALI20190410BHEP

Ipc: G16H 50/20 20180101AFI20190410BHEP

Ipc: G16H 50/70 20180101ALI20190410BHEP

Ipc: A61B 5/00 20060101ALI20190410BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61B0005000000

Ipc: G16H0050200000

A4 Supplementary search report drawn up and despatched

Effective date: 20190718

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/00 20060101ALI20190712BHEP

Ipc: C12Q 1/68 20180101ALI20190712BHEP

Ipc: G16H 50/70 20180101ALI20190712BHEP

Ipc: G16B 20/00 20190101ALI20190712BHEP

Ipc: G16B 40/20 20190101ALI20190712BHEP

Ipc: G16H 50/20 20180101AFI20190712BHEP

19U Interruption of proceedings before grant

Effective date: 20191011

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20201201

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PSOMAGEN, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231122